Want to see FULC full AI Analyst Report?
FULC Stock Chart & Stats
$8.29
-$0.39(-7.98%)
At close: 4:00 PM EST
$8.29
-$0.39(-7.98%)
Day’s Range― - ―
52-Week Range$2.83 - $15.74
Previous CloseN/A
Volume345.04K
Average Volume (3M)4.20M
Market Cap
$235.88M
Enterprise Value$145.00M
Total Cash (Recent Filing)$333.32M
Total Debt (Recent Filing)$5.87M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 05, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding66,633,320
10 Day Avg. Volume1,771,679
30 Day Avg. Volume4,198,029
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.05
Price to Sales (P/S)0.00
P/FCF Ratio-11.87
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.91
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$3.43Price Target Upside-58.64% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering8
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Multi-year RunwayFulcrum's very low leverage and ~$333M of cash provide structural financial flexibility, allowing the company multiple years to pursue strategic alternatives, fund discovery efforts or advance non-PRC2 programs without immediate financing pressure, reducing near-term liquidation risk.
Robust Clinical Proof‑of‑concept SignalsClear on‑target biology with large HbF increases, early VOC reduction and a clean short‑term safety profile validates the underlying mechanism and clinical approach. This durable scientific evidence strengthens platform credibility and informs development of next‑generation oral HbF inducers or partner programs.
Experienced Board And Dedicated Discovery CapabilityAdding sickle‑cell expertise to the board and retaining an internal discovery team preserves institutional knowledge and technical capability, enabling the company to design next‑generation candidates or package assets for partnerships, a durable advantage during strategic transition.
Bears Say
Discontinuation Of Pociredir ProgramEnding the lead sickle cell program is a structural setback: it removes the company's primary development asset and future value driver, forces a strategic reassessment, lowers near‑term approval probability and revenue prospects, and materially increases uncertainty about the firm's standalone development thesis.
Major Workforce Cuts And RestructuringAn ~85% headcount reduction materially reduces internal R&D and operational capacity, impairing the firm's ability to advance programs, generate new candidates, or negotiate from a position of strength; execution and timeline risk rise as reliance on external partners or transactions grows.
Zero Product Revenue And Persistent Cash BurnFulcrum remains pre‑revenue with sustained multi‑year losses and negative free cash flow, a structural financing risk despite current cash. Continued burn without product revenue increases the probability of dilutive financings, asset sales or partnerships to sustain operations beyond the existing runway.
Fulcrum Therapeutics News
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.83 and its highest was $15.74 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Fulcrum Therapeutics’s market cap is $235.88M.
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 21 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Apr 27, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Overvalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 66,633,320 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Currently, no hedge funds are holding shares in FULC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fulcrum Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.43 (-58.64% Downside)
$3.43 (-58.64% Downside)
Blogger Sentiment
Bullish
FULC Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 218.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.55%
12-Months-Change
Fundamentals
Return on Equity
-27.80%
Trailing 12-Months
Asset Growth
42.91%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
FULC Stock 12 Month Forecast
Average Price Target
$3.43
▼(-58.64% Downside)
Technical Analysis
Monopar Therapeutics Inc
―
ADC Therapeutics
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.25% Insiders
8.51% Mutual Funds
1.66% Other Institutional Investors
66.73% Public Companies and
Individual Investors